Results 41 to 50 of about 59,240 (301)

Re-medicalizing cannabis : science, medicine and policy, 1973 to the early twenty-first century [PDF]

When cannabis-based medicine was withdrawn in the UK in 1973 it appeared cannabis' career as a medicine had ended, but even as cannabis became regulated solely as an illicit drug, it appeared it was being re-medicalized.
Taylor, Suzanne
core   +1 more source

Acute toxicity of ADB‐CHMINACA ‐ a case series of patients with pronounced central nervous symptoms including the posterior reversible encephalopathic syndrome

British Journal of Clinical Pharmacology, EarlyView.
Aim This report presents a series of 16 patients who were admitted to the emergency department following confirmed intake of the potent synthetic cannabinoid ADB‐CHMINACA. Methods The cases are drawn from a prospective observational study following the recreational use of synthetic cannabinoids.
Maren Hermanns‐Clausen, Michaela Sommer, Annette Zschiesche, Verena Angerer, Martin Scheu, Florian Eyer, Johannes Nadler, Volker Auwärter   +7 more
wiley   +1 more source

Cannabidiol’s cytotoxicity in pancreatic cancer is induced via an upregulation of ceramide synthase 1 and ER stress

Journal of Cannabis Research
Pancreatic ductal adenocarcinoma (PDAC) remains one of the most aggressive malignancies with a median 5 year-survival rate of 12%. Cannabidiol (CBD) has been found to exhibit antineoplastic potential and may potentiate the anticancer effects of cytotoxic’
Nagina Mangal, Vikash Reebye, Nagy Habib, Mikael H. Sodergren   +3 more
doaj   +1 more source

High CBD extract (CBD-X) modulates inflammation and immune cell activity in rheumatoid arthritis

Frontiers in Immunology
IntroductionRheumatoid arthritis (RA) is a debilitating autoimmune disease affecting approximately 1% of the global population and is associated with significant morbidity and mortality.
Miran Aswad, Antonina Pechkovsky, Narmeen Ghanayiem, Haya Hamza, Igal Louria-Hayon, Igal Louria-Hayon   +5 more
doaj   +1 more source

Evaluation of Patient Reported Safety and Efficacy of Cannabis From a Survey of Medical Cannabis Patients in Canada

Frontiers in Public Health, 2021
With the medical use of cannabis permitted in Canada since 2001, patients seek to use this botanical drug to treat a range of medical conditions. However, many healthcare practitioners express the need for further scientific evidence around the use of ...
Shaina P. Cahill, Stephanie E. Lunn, Patrick Diaz, Jonathan E. Page, Jonathan E. Page   +4 more
doaj   +1 more source

Exploring new avenues: Psychedelic‐assisted therapy for young people

British Journal of Clinical Pharmacology, EarlyView.
Rates of mental illness in young people are increasing, whereas the development of novel mental health treatments has not significantly progressed. Psychedelic‐assisted therapy, using substances such as psilocybin and 3,4‐methylenedioxymethamphetamine (MDMA), has shown potential in the treatment of mental illnesses in the adult population, including ...
Ioanna Artemis Vamvakopoulou, Dasha Nicholls, David J. Nutt, Martina Di Simplicio   +3 more
wiley   +1 more source

High-CBD Extract (CBD-X) in Asthma Management: Reducing Th2-Driven Cytokine Secretion and Neutrophil/Eosinophil Activity

Pharmaceuticals
Background/Objectives: Asthma is a chronic inflammatory disorder of the airways affecting over 10% of the global population. It is characterized by airway inflammation, mucus hypersecretion, and bronchial hyperresponsiveness, driven predominantly by type
Miran Aswad, Antonina Pechkovsky, Narmeen Ghanayiem, Haya Hamza, Yaniv Dotan, Igal Louria-Hayon   +5 more
doaj   +1 more source

Exploring medical cannabis use in individuals with a traumatic brain injury

Exploration of Medicine, 2023
Aim: Traumatic brain injury (TBI) is a common neurological condition, which can present with a wide range of neuropsychological symptoms. Treating this broad spectrum of symptoms represents a significant medical challenge.
Elizabeth N. R. Schjelderup, Caroline A. MacCallum, Lindsay A. Lo, Jessie Dhillon, April Christiansen, Carly Pistawka, Kathryn Rintoul, William J. Panenka, Alasdair M. Barr   +8 more
doaj   +1 more source

Evaluation of a pantoprazole and 4‐desmethylpantoprazole‐sulfate metabolic ratio as a novel CYP2C19 phenotyping method

British Journal of Clinical Pharmacology, EarlyView.
Aims CYP2C19 is one of the most important pharmacogenes, and its activity is highly variable due to factors such as genetics or drug–drug interactions. Due to the lack of an appropriate endogenous CYP2C19 biomarker, surrogate methods to assess its activity are warranted.
Julian Peter Müller, Vladimir N. Belov, Sabrina Yamoune, Bob Miller, Mohammed Hasoumi, Jolanta Tupiec, Thea Laurentius, L. Cornelius Bollheimer, Julia C. Stingl, Katja S. Just   +9 more
wiley   +1 more source

Cannabigerol (CBG) Modulates Neutrophil Activity and Ameliorates Rheumatoid Arthritis Pathogenesis

Pharmaceuticals
Background/Objectives: Rheumatoid arthritis (RA) is a chronic, inflammatory, autoimmune disease that primarily affects the joints. Current treatments aim to relieve pain and limit joint damage; however, many are associated with significant side effects ...
Miran Aswad, Antonina Pechkovsky, Haya Hamza, Igal Louria-Hayon   +3 more
doaj   +1 more source